[{"id":"e4b8dc13-2fa4-4dfc-9ca2-9c244ab329af","acronym":"VX0120","url":"https://clinicaltrials.gov/study/NCT05901285","created_at":"2024-03-07T20:32:48.000Z","updated_at":"2025-02-25T15:13:32.267Z","phase":"Phase 1","brief_title":"Phase 1 Study of Intratumoral Administration of VAX014 in Subjects with Advanced Solid Tumors","source_id_and_acronym":"NCT05901285 - VX0120","lead_sponsor":"Vaxiion Therapeutics","biomarkers":" STING","pipe":"","alterations":" ","tags":["STING"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VAX014 intratumoral"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 11/02/2023","start_date":" 11/02/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-13"},{"id":"356e3601-303f-449c-86cb-daf647b519de","acronym":"","url":"https://clinicaltrials.gov/study/NCT06532539","created_at":"2025-02-25T16:28:03.858Z","updated_at":"2025-02-25T16:28:03.858Z","phase":"Phase 2","brief_title":"Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma","source_id_and_acronym":"NCT06532539","lead_sponsor":"Shandong Cancer Hospital and Institute","biomarkers":" CD8 • PD-1 • TIGIT • NCAM1 • STING • CD68 • PVR","pipe":"","alterations":" ","tags":["CD8 • PD-1 • TIGIT • NCAM1 • STING • CD68 • PVR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/13/2024","start_date":" 06/13/2024","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-08-01"},{"id":"69cfd09d-b523-4d6f-8866-3ce4d4429ba4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05744089","created_at":"2023-02-24T16:01:33.149Z","updated_at":"2024-07-02T16:35:54.594Z","phase":"","brief_title":"Home Management of Simple Hydromorphone PCA Pump Mode","source_id_and_acronym":"NCT05744089","lead_sponsor":"The First Affiliated Hospital of Xinxiang Medical College","biomarkers":" IL6 • CD4 • IL2 • STING","pipe":"","alterations":" ","tags":["IL6 • CD4 • IL2 • STING"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-02-28"},{"id":"c692fc36-4914-4658-8837-ab9ef9c82921","acronym":"","url":"https://clinicaltrials.gov/study/NCT02986867","created_at":"2021-01-18T14:41:36.608Z","updated_at":"2024-07-02T16:37:03.959Z","phase":"","brief_title":"SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma","source_id_and_acronym":"NCT02986867","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" STING","pipe":"","alterations":" ","tags":["STING"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 06/13/2017","start_date":" 06/13/2017","primary_txt":" Primary completion: 03/07/2018","primary_completion_date":" 03/07/2018","study_txt":" Completion: 03/07/2018","study_completion_date":" 03/07/2018","last_update_posted":"2019-01-10"}]